vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Five9, Inc. (FIVN). Click either name above to swap in a different company.
Five9, Inc. is the larger business by last-quarter revenue ($300.3M vs $168.4M, roughly 1.8× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 7.8%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 10.3%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Five9, Inc. is a leading global provider of cloud-native contact center software and solutions. It serves enterprises of all sizes across retail, healthcare, financial services, and technology sectors, offering omnichannel customer engagement tools, AI-powered automation, workforce management, and analytics to boost customer experience and operational efficiency.
ESPR vs FIVN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $300.3M |
| Net Profit | — | — |
| Gross Margin | — | 55.4% |
| Operating Margin | 50.6% | 6.6% |
| Net Margin | — | — |
| Revenue YoY | 143.7% | 7.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $300.3M | ||
| Q3 25 | $87.3M | $285.8M | ||
| Q2 25 | $82.4M | $283.3M | ||
| Q1 25 | $65.0M | $279.7M | ||
| Q4 24 | $69.1M | $278.7M | ||
| Q3 24 | $51.6M | $264.2M | ||
| Q2 24 | $73.8M | $252.1M | ||
| Q1 24 | $137.7M | $247.0M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $18.0M | ||
| Q2 25 | $-12.7M | $1.2M | ||
| Q1 25 | $-40.5M | $576.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $-4.5M | ||
| Q2 24 | $-61.9M | $-12.8M | ||
| Q1 24 | $61.0M | $-7.1M |
| Q4 25 | — | 55.4% | ||
| Q3 25 | — | 55.0% | ||
| Q2 25 | — | 54.9% | ||
| Q1 25 | — | 55.0% | ||
| Q4 24 | — | 56.0% | ||
| Q3 24 | — | 53.8% | ||
| Q2 24 | — | 53.0% | ||
| Q1 24 | — | 53.6% |
| Q4 25 | 50.6% | 6.6% | ||
| Q3 25 | -11.4% | 5.6% | ||
| Q2 25 | 8.6% | -0.6% | ||
| Q1 25 | -34.0% | -1.9% | ||
| Q4 24 | -6.4% | 1.5% | ||
| Q3 24 | -31.0% | -5.8% | ||
| Q2 24 | 3.5% | -7.7% | ||
| Q1 24 | 52.5% | -8.4% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 6.3% | ||
| Q2 25 | -15.4% | 0.4% | ||
| Q1 25 | -62.2% | 0.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | -1.7% | ||
| Q2 24 | -83.9% | -5.1% | ||
| Q1 24 | 44.3% | -2.9% |
| Q4 25 | $0.32 | $0.22 | ||
| Q3 25 | $-0.16 | $0.21 | ||
| Q2 25 | $-0.06 | $0.01 | ||
| Q1 25 | $-0.21 | $0.01 | ||
| Q4 24 | $-0.14 | $0.16 | ||
| Q3 24 | $-0.15 | $-0.06 | ||
| Q2 24 | $-0.33 | $-0.17 | ||
| Q1 24 | $0.34 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $232.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $785.8M |
| Total Assets | $465.9M | $1.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $232.1M | ||
| Q3 25 | $92.4M | $193.4M | ||
| Q2 25 | $86.1M | $205.5M | ||
| Q1 25 | $114.6M | $370.3M | ||
| Q4 24 | $144.8M | $362.5M | ||
| Q3 24 | $144.7M | $291.0M | ||
| Q2 24 | $189.3M | $175.7M | ||
| Q1 24 | $226.6M | $240.2M |
| Q4 25 | $-302.0M | $785.8M | ||
| Q3 25 | $-451.4M | $775.3M | ||
| Q2 25 | $-433.5M | $717.4M | ||
| Q1 25 | $-426.2M | $664.3M | ||
| Q4 24 | $-388.7M | $622.2M | ||
| Q3 24 | $-370.2M | $565.6M | ||
| Q2 24 | $-344.2M | $525.9M | ||
| Q1 24 | $-294.3M | $483.6M |
| Q4 25 | $465.9M | $1.8B | ||
| Q3 25 | $364.0M | $1.8B | ||
| Q2 25 | $347.1M | $1.7B | ||
| Q1 25 | $324.0M | $2.1B | ||
| Q4 24 | $343.8M | $2.1B | ||
| Q3 24 | $314.1M | $2.0B | ||
| Q2 24 | $352.3M | $1.9B | ||
| Q1 24 | $373.1M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $83.6M |
| Free Cash FlowOCF − Capex | — | $77.3M |
| FCF MarginFCF / Revenue | — | 25.8% |
| Capex IntensityCapex / Revenue | 0.0% | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $201.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $83.6M | ||
| Q3 25 | $-4.3M | $59.2M | ||
| Q2 25 | $-31.4M | $35.1M | ||
| Q1 25 | $-22.6M | $48.4M | ||
| Q4 24 | $-35.0M | $49.8M | ||
| Q3 24 | $-35.3M | $41.1M | ||
| Q2 24 | $-7.2M | $19.9M | ||
| Q1 24 | $53.8M | $32.4M |
| Q4 25 | — | $77.3M | ||
| Q3 25 | — | $48.7M | ||
| Q2 25 | — | $31.6M | ||
| Q1 25 | — | $43.7M | ||
| Q4 24 | — | $40.5M | ||
| Q3 24 | $-35.5M | $26.7M | ||
| Q2 24 | $-7.3M | $13.1M | ||
| Q1 24 | $53.8M | $20.4M |
| Q4 25 | — | 25.8% | ||
| Q3 25 | — | 17.0% | ||
| Q2 25 | — | 11.1% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | — | 14.5% | ||
| Q3 24 | -68.7% | 10.1% | ||
| Q2 24 | -9.9% | 5.2% | ||
| Q1 24 | 39.0% | 8.3% |
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 3.7% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.0% | 3.3% | ||
| Q3 24 | 0.3% | 5.4% | ||
| Q2 24 | 0.1% | 2.7% | ||
| Q1 24 | 0.1% | 4.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.29× | ||
| Q2 25 | — | 30.38× | ||
| Q1 25 | — | 84.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FIVN
Segment breakdown not available.
